Thomas Landwehr

Learn More
The cell-surface glycoprotein CD44 is expressed in chronic lymphocytic leukemia (CLL), but its functional role in this disease is poorly characterized. We therefore investigated the contribution of CD44 to CLL in a murine disease model, the Eµ-TCL1 transgenic mouse, and in CLL patients. Surface CD44 increased during murine CLL development. CD44 expression(More)
Monoclonal antibodies (mAbs) have become an important part of combination therapies against chronic lymphocytic leukaemia (CLL), for patients without and with comorbidity (Hallek et al, 2010; Furman et al, 2014; Goede et al, 2014). As a target antigen, CD37 may offer higher and more homogeneous expression on CLL cells than CD20. The Fc-engineered CD37(More)
Pharmacological inhibition of phosphatiylinositide-3-kinase (PI3K)-mediated signaling holds great promise for treating chronic lymphocytic leukemia (CLL). Therefore we assessed three structurally related PI3K inhibitors targeting the PI3K-δ isoform for their ability to inhibit the survival of freshly isolated CLL cells. The purely PI3K-δ-selective inhibitor(More)
  • 1